Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Nuvama’s research report on 101 emerging companies small and micro-cap stocks



Nuvama’s annual knowledge and corporate access event – Edelweiss Emerging Ideas Conference 2023: India – UDYAN ‘Udayan: Udyog, Avasanrachana, Nivesha – was a resounding success. Held between December 5th-6th, 2023, the conference saw participation from more than 55+ corporates (including 25+ CEOs), 320+ clients across over 4000+ meetings.

Underlying the theme, India’s economy stands on the cusp of unprecedented growth compared to global peers. Our beliefs were further reinforced by the corporate commentary we heard at the conference for India’s sustainable long term growth

Nuvama has issued a research report containing crisp data on 101 emerging companies (i.e small and micro-cap companies. The report covers mega multibaggers like Vasa Dentisity etc in which noted investors like Ashish Kacholia, Mukul Agarwal, Madhu Kela, Porinju etc are invested.

Download Nuvama’s research report on 101 emerging companies small and micro-cap stocks

investments

No Comments Yet

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 494 other subscribers

RSS Stocks Talk Forum

  • Shalby is a multi-specialty hospital chain with expertise in joint replacement
    Shalby is a multi-specialty hospital chain with expertise in joint replacement. It is making right strides with calibrated growth based on big ticket expansion in metros & tier I cities & asset-light franchisee expansion in tier II-VI towns. TP ₹310 (35%) Download... Shalby is a multi-specialty hospital chain with expertise in joint replacement
  • DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
    DLF has strong growth prospects due to strong sectoral tailwinds, record low inventory, greater preference for branded luxury, extensive launch pipeline & expansion in its annuity portfolio. Strong Balance Sheet with consistent cash flow. TP ₹1081 (+30%) Research Report... DLF has strong growth prospects. Buy for target price of ₹1081 (30% upside)
  • Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
    Aditya Birla Capital has demonstrated solid performance, achieving strong growth in the loan book while maintaining asset quality. Management has reiterated guidance on both growth & credit cost fronts. Lending business expected to grow at 30%. TP (+37%)... Aditya Birla Capital has demonstrated solid performance. Buy for target price of ₹280 (37% upside)
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!